TGFB1 and neoplasm: They are much harder to study and quantify than genetic changes and may reflect responses to applied therapeutic immune pressure or be related to other features of cancer progression and the tumor microenvironment including TGF-β signaling [18], ER stress [19] and hypoxia [20].